- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04928482
Réponses à l'entraînement à la marche arrière après un AVC (BRAVE)
Réponses cérébrales et comportementales à l'entraînement à la marche arrière après un AVC
Approximately 15,000 Veterans are hospitalized for stroke each year with new cases costing an estimated $111 million for acute inpatient, $75 million for post-acute inpatient, and $88 million for follow-up care over 6 months post-stroke. The investigators have previously established the effectiveness of a backward walking training program to improve gait and balance in post-stroke Veterans. To best serve Veterans in this era of personalized medicine, there is a current need to determine the appropriate training dose as well as which post-stroke Veterans would most benefit. This study addresses both needs as it will 1) test responses to two different doses (18 vs. 27 sessions) of backward walking training and 2) assess brain activity, measured by magnetic resonance imaging, before and after training intervention to determine its ability to predict rehabilitation response as well as brain mechanisms of behavioral change.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This prospective, single-blind, randomized controlled trial will enroll individuals between 2- and 4-months post-stroke and is designed to address the study's three Specific Aims (See Figure below). The study will be approved by an ethics review board and all participants will provide written informed consent. Baseline pre-intervention assessment (Assessment A) will consist of clinical gait and balance assessments and resting state Functional Connectivity MRI and functional MRI. Brain imaging at Assessment A will test the hypotheses that rs-FC and fMRI can predict BWTraining intervention response (Specific Aim 2). Following Assessment A, participants will be randomized to receive 1) 18 sessions or 2) 27-sessions of BWTraining 3x/week for six or nine weeks respectively. Participants in the 18-session group will wait 3 weeks following randomization to begin training such that Assessment B will take place at approximately the same time post-stroke for all participants. This will assure that all participants have had the same duration of time post-stroke after study enrollment to experience spontaneous recovery. Gait and balance measures at Assessment B will be compared to Assessment A to test Specific Aim #1. MRI brain measurements at Assessment B will be compared to those at Assessment A to test the hypotheses of exploratory Aim #3. Assessment C, at six weeks post-intervention will evaluate short-term and Assessment D, at 6-months post-intervention will evaluate long-term retention gains in gait and balance. The investigators will recruit 54 individuals post-stroke to allow up to a 10% attrition rate and still provide a sufficient participant pool (n=48) to address the Specific Aims.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
Gainesville, Florida, États-Unis, 32608-1135
- North Florida/South Georgia Veterans Health System, Gainesville, FL
-
Jacksonville, Florida, États-Unis, 32216
- Brooks Rehabilitation
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Berg Balance Scale < 45
- Self-selected 10 meter gait speed < 0.8 meters/second (m/s)
- Diagnosis of unilateral stroke
- > 2 months < 4 months post-stroke
- Able to ambulate at least 10 feet with maximum 1 person assist
- Medically stable
Exclusion Criteria:
-
Presence of neurological condition other than stroke
-
Serious cardiac conditions (hospitalization for myocardial infarction or heart surgery within 3 months, history of congestive heart failure, documented serious and unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living)
- Anyone meeting New York Heart Association criteria for Class 3 or Class 4 heart disease will be excluded
-
Severe arthritis or orthopedic problems that limit passive ranges of motion of lower extremity (knee flexion contracture of -10 degrees, knee flexion ROM < 90 degrees, hip flexion contracture > 25 degrees, and ankle plantar flexion contracture > 15 degrees)
-
Severe hypertension with systolic greater than 200 millimeter of mercury (mmHg) and diastolic greater than 110 millimeter of mercury (mmHg) at rest
-
Pain upon ambulation
-
Receiving physical therapy services for mobility and/or gait
-
Living in a skilled nursing facility
-
Any magnetic resonance imaging (MRI) contraindication, including but not limited to the presence of metal, magnetic resonance (MR) sensitive implanted medical devices, or claustrophobia
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 27 session group
Participants in this arm will receive 27 sessions of backward walking training. |
Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. |
|
Comparateur actif: 18 session group
Participants in this arm will receive 18 sessions of backward walking training. |
Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in the time to complete the 10 Meter walk Test
Délai: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
Gait speed will be measured with the 10-Meter Walk Test. Individuals will be given a 3 meter warm-up distance for walking, preceding the 10 meter distance and 3 meters beyond the 10 meters to continue walking. The time that it takes to traverse the 10 meters at the subject's usual pace will be recorded. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the time to complete the Three-Meter Backward Walk Test
Délai: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
Backward (BW) Speed will be assessed with the 3-Meter Backward Walk test (3MBWT). The test consists of a 1 meter warm-up distance, a timed 3 meter distance, followed by an additional 1 meter to continue walking. An average of two trials will be recorded. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the Functional Gait Assessment
Délai: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
A 10-item clinical gait and balance test of dynamic activities. Reported scores range from 0 to 30 with a larger number representing a better score. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the Activity-Specific Balance Confidence Scale
Délai: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
This 16-item self-report measure is used to assess perceived efficacy (self-reported confidence) in maintaining balance while performing a number of activities common in community-dwelling older adults. This scale is reported as an average of the 16 items from 0% to 100% with a larger number representing a better score. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
|
Change in the Berg Balance Scale
Délai: Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
This tool consists of 14 items that assesses static and dynamic standing balance, ability to sit, stand up and transfer. The range of this scale is 0-56 with a larger number representing a better score. |
Change from baseline to end of study intervention (six or nine weeks depending on intervention arm)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in the time to complete the 10 Meter walk Test
Délai: Change from baseline through study completion, an average of 7 months.
|
Gait speed will be measured with the 10-Meter Walk Test. Individuals will be given a 3 meter warm-up distance for walking, preceding the 10 meter distance and 3 meters beyond the 10 meters to continue walking. The time that it takes to traverse the 10 meters at the subject's usual pace will be recorded. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the time to complete the Three-Meter Backward Walk Test
Délai: Change from baseline through study completion, an average of 7 months.
|
BW Speed will be assessed with the 3-Meter Backward Walk test (3MBWT). The test consists of a 1 meter warm-up distance, a timed 3 meter distance, followed by an additional 1 meter to continue walking. An average of two trials will be recorded. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the Functional Gait Assessment
Délai: Change from baseline through study completion, an average of 7 months.
|
A 10-item clinical gait and balance test of dynamic activities. Reported scores range from 0 to 30 with a larger number representing a better score. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the Activity-Specific Balance Confidence Scale
Délai: Change from baseline through study completion, an average of 7 months.
|
This 16-item self-report measure is used to assess perceived efficacy (self-reported confidence) in maintaining balance while performing a number of activities common in community-dwelling older adults. This scale is reported as an average of the 16 items from 0% to 100% with a larger number representing a better score. |
Change from baseline through study completion, an average of 7 months.
|
|
Change in the Berg Balance Scale
Délai: Change from baseline through study completion, an average of 7 months.
|
This tool consists of 14 items that assesses static and dynamic standing balance, ability to sit, stand up and transfer. The range of this scale is 0-56 with a larger number representing a better score. |
Change from baseline through study completion, an average of 7 months.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Dorian Kay Rose, PhD MS BS, North Florida/South Georgia Veterans Health System, Gainesville, FL
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- B3542-R
- 5I01RX003542-05 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .